CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.20, no.8, 2020 (SCI-Expanded)
Article / Review
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
EAP, Efficacy, RRMM, Safety, Survival, REFRACTORY MULTIPLE-MYELOMA, HISTORICAL CONTROL DATA, OPEN-LABEL, SURVIVAL, EFFICACY, CD38
Dokuz Eylül University Affiliated:
The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile.